Transition Therapeutics pulls in $31M; Martoma faces nearly 20 years for insider trading;

@FierceBiotech: The search is on for 2014's Fiercest biotech startups. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Story | Follow @JohnCFierce

@DamianFierce: Follow @FiercePharma as @EricPFierce and @JonEPVantage wrap #ASCO14. Or tune in here: Twitter chat | Follow @DamianFierce

@EmilyMFierce: Collaborative KPI Therapeutics launches to beef up Kineta's pipeline. Article | Follow @EmilyMFierce

> Toronto's Transition Therapeutics ($TTHI) raised $30.8 million in a private placement, money it will use to complete Phase II trials of ELND005, a treatment for Alzheimer's disease side effects, and TT-401, a Type 2 diabetes drug. News

> Mathew Martoma, the former SAC Capital Advisors hedge fund convicted of biotech insider trading, successfully delayed his pending sentencing. Martoma faces between 15.7 years and 19.6 years in prison under sentencing guidelines, setting him up for what could be the longest prison term handed to anyone convicted in such a case. Story

Medical Device News

@FierceMedDev: London's Institute of Cancer Research to help develop MRI-guided radiation systems. More | Follow @FierceMedDev

@VarunSaxena2: A working group recommended $4.5 billion over 12 years in funding for NIH's BRAIN initiative. Story | Follow @VarunSaxena2

@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. Article | Follow @MichaelGFierce

@EmilyWFierce: New test that pinpoints multiple genes in a tumor could replace companion Dx as a tool for diagnosing cancer. Story | Follow @EmilyWFierce

> FDA beefs up cybersecurity efforts to ensure safety standards. More

> Kleiner Perkins, TPG-backed heart transplant monitor company files for $50M IPO. Story

Pharma News

@FiercePharma: Ranbaxy decision shows why FDA reluctant to rely on European inspections. More | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? LinkedIn discussion | Follow @TracyStaton

@EricPFierce: More action in sterile injectables. Amneal said to be trying to buy India's Epsilon Pharmaceuticals. Story | Follow @EricPFierce

@CarlyHFierce: Still trending on FierceVaccines: The top 10 best-selling vaccines of 2013. Report | Follow @CarlyHFierce

@JustinHFierce:  Because mad cow disease is scary, when you actually think about it. Article | Follow @JustinHFierce

> Sanofi, Lilly prep OTC Cialis to compete against counterfeit ED pills. Story

> Sanofi CEO: No deals? No problem. More

> Group again petitions FDA to ban Novo Nordisk's Victoza. News

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.